Combination therapy improved survival and reduced toxicity in patients with advanced non-small cell lung cancer, indicating its potential as a treatment strategy.
Medium-dose anlotinib combined with PD-1 therapy delivers superior survival and QoL outcomes with manageable toxicity. These results underscore its potential as an optimal treatment strategy for advanced NSCLC.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: